Vaxcyte Bilan de santé

Santé financière contrôle des critères 6/6

Vaxcyte possède un total de capitaux propres de $3.4B et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $3.6B et de $142.1M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$2.18b
Fonds propres	US$3.42b
Total du passif	US$142.11m
Total des actifs	US$3.56b

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 5VA ( $2.2B ) dépassent ses passifs à court terme ( $123.8M ).

Passif à long terme: Les actifs à court terme de 5VA ( $2.2B ) dépassent ses passifs à long terme ( $18.3M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 5VA est sans dette.

Réduire la dette: 5VA n'a aucune dette par rapport à il y a 5 ans, lorsque son ratio d'endettement était 1.1%.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: 5VA dispose d'une piste de trésorerie suffisante pour plus de 3 ans sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: 5VA dispose d'une marge de trésorerie suffisante pour plus de 3 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 50.3 % chaque année

Vaxcyte Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

Vaxcyte, Inc. Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

Insufficient new directors

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $1.299998 billion.

New major risk - Revenue and earnings growth

Vaxcyte, Inc. has filed a Follow-on Equity Offering.

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Vaxcyte Appoints John Furey to Board of Directors

Vaxcyte, Inc., Annual General Meeting, Jun 06, 2024

New major risk - Revenue and earnings growth

Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

New major risk - Revenue and earnings growth

Vaxcyte, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.

Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer

Vaxcyte, Inc. Provides Clinical and Regulatory Progress Update on Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise

Vaxcyte, Inc. Announces the Publication of the Results from the VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in the Journal The Lancet Infectious Diseases

Vaxcyte, Inc. Appoints Jacks Lee to Board of Directors

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults

Vaxcyte, Inc. Announces FDA Clearance of Investigational New Drug Application for Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults

Vaxcyte, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Vaxcyte’S VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults

Vaxcyte, Inc. Announces Executive Changes, Effective January 1, 2023

High number of new directors

Vaxcyte, Inc. Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24 Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64

Vaxcyte, Inc. Announces Executive Appointments

Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older

Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Vaxcyte, Inc. Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-Of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of Vax-24 in Adults

High number of new directors

Vaxcyte, Inc., Annual General Meeting, Jun 01, 2022

Vaxcyte, Inc. Announces Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in Adults

Vaxcyte, Inc. Announces the First Participants Dose in the Phase 1/2 Clinical Study of VAX-24

Vaxcyte, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease

Less than half of directors are independent

Vaxcyte, Inc. Announces Publication of Preclinical Data Supporting the Potential of VAX-24 for the Prevention of Invasive Pneumococcal Disease

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines